Arthur MacHlenkin

Arthur Machlenkin has a diverse and extensive work experience in the field of scientific research and biotechnology. Arthur currently holds the position of Chief Scientific Officer at Pluri since January 2023. Prior to this role, they served as the VP of Research at Pluri from May 2022 to January 2023.

Before joining Pluri, Arthur worked as a Consultant at Weizmann Institute of Science from November 2021 to May 2022, and at KAHR-Medical Ltd. from October 2021 to May 2022.

From December 2017 to September 2021, Arthur served as the CEO of Pantheon Biosciences. Arthur also held the position of Director and Head of Immuno-Oncology Research at Compugen Ltd. from February 2014 to December 2017.

Arthur's work experience also includes being a Principal Investigator at Hadassah University Medical Center from October 2004 to January 2014, and a Project Lead at Combact Diagnostic Systems Ltd. from January 1997 to January 1999.

Overall, with their broad range of roles and responsibilities, Arthur Machlenkin has gained significant expertise and knowledge in the scientific research and biotechnology industry.

Arthur Machlenkin has a PhD in Tumor Biology and Cancer Immunotherapy from the Weizmann Institute of Science, which they obtained from 1999 to 2004. Arthur also holds a Master of Science (MSc) degree in Cancer Research, Vitamin D, and Cancer from Tel Aviv University, which they completed from 1993 to 1995. Additionally, they attended Tel-Aviv University - Lahav Executive Education in 2019 to pursue further education in Directors and Other Senior Corporate Officeholders, although no specific degree or field of study is mentioned for this program.